Pregabalin (All indications)

Cognitive developmental disorders/delay (> 6 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12754
R53775		 Bjørk (Controls exposed to Lamotrigine, sick) (Other indications), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 0.88 [0.34;2.30] C
excluded (control group) 		5/1,666   27/7,950 32 1,666
ref
S12755
R53776		 Bjørk (Controls unexposed NOS) (Other indications), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes 1.01 [0.42;2.43]
excluded (control group) 		5/1,666   16,384/4,463,879 16,389 1,666
ref
S12756
R53777		 Bjørk (Controls unexposed, sick) (Other indications), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 0.47 [0.19;1.14] C 5/1,666   139/21,634 144 1,666
ref
Total 1 studies 0.47 [0.19;1.14] 144 1,666
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bjørk (Controls unexposed, sick) (Other indications), 2022Bjørk, 2022 1 0.47[0.19; 1.14]1441,6660%ROB confusion: unclearROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick) (Other indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.47[0.19; 1.14]1441,666 -NABjørk (Controls unexposed, sick) (Other indications), 2022 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.47[0.19; 1.14]1441,666 -NABjørk (Controls unexposed, sick) (Other indications), 2022 1 Tags Adjustment   - No  - No 0.47[0.19; 1.14]1441,666 -NABjørk (Controls unexposed, sick) (Other indications), 2022 1 Controls   - epilepsy indication  - epilepsy indication 0.47[0.19; 1.14]1441,666 -NABjørk (Controls unexposed, sick) (Other indications), 2022 1 All studiesAll studies 0.47[0.19; 1.14]1441,666 -NABjørk (Controls unexposed, sick) (Other indications), 2022 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12754, 12755

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.01[0.42; 2.43]16,3891,666 -NABjørk (Controls unexposed NOS) (Other indications), 2022 1 unexposed, sick controlsunexposed, sick controls Out of scale0.47[0.19; 1.14]1441,666 -NABjørk (Controls unexposed, sick) (Other indications), 2022 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.88[0.34; 2.30]321,666 -NABjørk (Controls exposed to Lamotrigine, sick) (Other indications), 2022 10.510.01.0